Trial challenges COPD drug fears

Tiotropium cuts mortality in COPD patients by 16 per cent compared with placebo, results of a 5,993-patient study show.

The long-acting anticholinergic drug, marketed as Spiriva, reduced exacerbations, delayed time to first exacerbation and cut the risk of exacerbations leading to hospital admission.

However, it failed to statistically significantly reduce decline in FEV1 after four years, the trial's primary endpoint.

The finding of reduced mortality contrasts with a recent JAMA analysis suggesting anticholinergics raise CVD risk.

  • NEJM 2008; 359: 1,543-54.

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in